The Committee for Medicinal Products for Human Use (CHMP) carries out scientific assessments for the European Medicines Agency and recommends whether medicines submitted through the centralized procedure should be granted marketing authorizations. The committee also prepares scientific and regulatory guidelines and monitors adverse drug reaction reports.
Once approved by the European Commission, a centralized marketing authorization is valid in all EU member states as well as Iceland, Liechtenstein and Norway